PROF. DR. NAZİMİ AÇIKGÖZ: RUSSIA'S GREAT INVESTMENT IN GENETICS AND BREEDING
Russia’s Great Investment in Genetics and Breeding
Posted by Nazimi Acikgoz on 23/06/2019
In an unexpected period, Russia announced that it has allocated a large amount of new breeding technologies[1]. According to information from the Russian Academy of Sciences (RAS), the targets of this US $ 1.7 billion investment of have been set to develop 10 new varieties of gene-edited crops and animals by 2020 and another set of 20 gene-edited varieties by 2027. The main aim of the project is to develop new varieties resistant to diseases in culture plants such as barley, sugar beet, wheat and
potato.
Mutation, selection, hybridization and similar classical breeding techniques have been used for breeding new genotypes that are adaptable to varying environmental conditions. Recently tissue culture, gene transfer and other molecular biologic developments have been also used. But in the last decades artificial mutations by using -X, gamma and similar radioactive rays- have served to plant breeders to breed thousands of new varieties. Mutation is a spontaneous or intentional change in living organism. Since 2010, this process has begun to be carried out in laboratories by molecular basis, with genomic arrangements. In this method, genotypes can be improved in a short time and reach the farmers. Gene regulation includes a number of new gene engineering methods such as CRISPR. In these methods, there is no transfer of any gene from outside like there is in GMOs. On the contrary, new genotypes are created by changing the target gene with the help of transient DNA-cutting enzymes. This application can increase or decrease the effect of gene. We can also call this process artificial micro-mutation.
GMOs are registered after passing through many risk tests such as environment and health before they are introduced to the consumers. Therefore, the cost of a genotype to the company exceeds US$ 100 million which is the main reason GMO and global multinational corporations have become synonymous. On the other hand the cost of developing genotypes with gene editing is almost 1/10th of GMO’s, therefore they can be utilized even by low-budget new startups, universities and even public institutions[2].
In 2018, the first commercial product of genome editing animal, tilapia developed with this new method was commercialized in Argentina[3]. It is the fourth most consumed sea product after shrimp, salmon and canned tuna. At the beginning of 2019, the oil of the new soybean variety[4], which was developed by the same method in the USA, took its place on the market shelves. The oil of this improved variety contains several times less “saturated fatty acids” and healthier oleic acid than ordinary soybeans.
Comments
Post a Comment